Amgen Inc. (AMGN) announced Friday morning that the 27,564-patient study of Repatha found that adding the drug to optimized statin therapy resulted in a statistically significant 20 percent reduction in heart attack, stroke or cardiovascular death. While the results were encouraging, analysts frowned upon the hefty price tag the drug will carry.
from RTT - Before the Bell http://ift.tt/2nrljOL
via IFTTT
No comments:
Post a Comment